Observational Study of Males With Creatine Transporter Deficiency

Ultragenyx Pharmaceutical Inc50 enrolled

Overview

The objectives of this study are to illustrate the clinical, neuro/electrophysiologic, biochemical, and developmental status and progression of patients with Creatine Transporter Deficiency (CTD) and to evaluate the utility of performance-based and other measures in the CTD population.

This is an observational study designed to determine an appropriate clinical assessment battery for males with CTD, and to evaluate Magnetic resonance spectroscopy (MRS) along with other potential biomarkers. It is designed to explore developmental domains of interest and to examine the feasibility and utility of various neuropsychological assessments to measure domains of interest, and to identify possible endpoints for interventional studies. Study will also explore genotype-phenotype correlations. Clinical adverse events will be monitored throughout the study. This study was previously posted by Lumos Pharma, which has been transferred to Ultragenyx in June 2019.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Creatine Deficiency, X-linked

Eligibility

Sex: MALEMin age: 6 MonthsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Subject has genomic confirmation of a pathologic mutation in the SLC6A8 gene. 2. Subject is able to complete study-related procedures. 3. Subjects' parents/guardians/caregivers must provide written consent (informed consent) to study-related procedures, and if appropriate, the subject will provide an assent. Exclusion Criteria: 1. Subject has had status epilepticus within 3 months of screening. 2. Subject is unable to comply with the study procedures or with a clinical disease or laboratory abnormality that in the opinion of the investigator would potentially increase the risk of participation.

Locations (10)

University of California San Diego

La Jolla, California, United States

Rush University Medical Center

Chicago, Illinois, United States

National Institutes of Health Clinical Center

Bethesda, Maryland, United States

Outcomes

Primary Outcomes

Change Over Time Through Month 48 in the Bayley Scales of Infant and Toddler Development, 4th Edition (Bayley-4)

Time frame: Month 48

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.